Navigation Links
NCX in Medical Technology
NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
SOPHIA ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today provided an update on the phase 2a study for NCX 1000, which is covered by its codevelopment agreement with Axcan Pharma Inc. A preliminary analysis of 11 patients from this proof-of-concept study in...Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
...se 2 proof-of-concept study for TPI 1020 (formerly ncx 1020) in Chronic Obstructive Pulmonary Disease (CO...ca and an option to obtain rest of world rights. ncx 4016 ncx 4016 is a nitric oxide-donating derivative of acet...... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer I...
NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
... focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...NicOx' Naproxcinod ABPM Data Presented at American Heart Association
... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
...res, Argentina. These included phase 1 results for ncx 1022, a prototype compound, showing the potential ...edical services. Furthermore, the clinical data on ncx 1022 suggest that nitric oxide donation may also i...owing encouraging results from a phase 1 study for ncx 1022, a lower potency prototype (see top-line resu...NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...NCX in Biological News
Biophysical Society announces 2008 International Travel Awards
...omputational Model of Ventricular Tissue. Carlo Manno, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela, Importance of ncx in the Regulation of Ca2+ Homeostasis in Skeletal Muscle. Maria V. Mernea, University of Bucharest, Romania, A Three-Dimensional Model of Epit...NCX in Biological Technology
NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer I...NicOx Opens U.S. Headquarters in New Jersey
... focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and ncx 4016, in phase 2 for type 2 diabetes. NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer In...Other TagsOther Contents
confrontsnibblingagressivenessSibutraminedecongestantdebatesrecuperationGilafoetusRiggedlabelsOTCdurationgrave
(Date:6/19/2013)... (PRWEB) June 19, 2013 Blueforce ... and sensor machine software, today announced it has ... its Decentralized Fusion Engine technology. The award ... the acquisition of key strategic partnerships. , ... wireless collaboration and machine-to-machine (M2M) software products that ...
(Date:6/19/2013)... A blow to the head; a swift jarring to ... to hours. It’s understandable, but what else may follow ... traumatic brain injury. According to mayoclinic.com , usual ... But many other symptoms may follow, sometimes not for ... include ongoing headaches, dizziness, feeling like you’re in a fog, ...
(Date:6/19/2013)... 19, 2013 Walkingspree, a specialized wellness ... the launch of its new Facebook App. This is ... inspire participants to reach their program fitness goals. Consistent ... Walkingspree clients are given more tools to customize their ... , Corporate clients may choose whether or not they ...
(Date:6/19/2013)... Weight gain and obesity have been ... including heart disease, kidney failure and high blood pressure. ... and unnecessary fat, have many people searching for fast ... diets to not only allow patients to succeed ... aim to reduce the risk for many weight-related health ...
(Date:6/19/2013)... June 19, 2013 The reason for the ... because users can place a 4x8 flood tray inside the ... to work around. In addition, Gorilla Grow Tents are ... are the tallest, thickest and strongest grow tents on the ... grow tent standards. , Gorilla Grow Tents are ...
Breaking Medicine News(10 mins):Health News:Blueforce Awarded Patent for Decentralized Sensor Fusion 2Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns 3Health News:Stealth Grow Tent Brand’s Popularity Rises 2[0] Blueforce Awarded Patent for Decentralized Sensor Fusion[0] Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist[0] Walkingspree’s New Facebook Connectivity Boosts Accountability and Engagement[0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Fast Weight Loss Programs for Patients Suffering with Health Care Concerns[0] Stealth Grow Tent Brand’s Popularity Rises
(Date:6/18/2013)... Arlington environmental engineer has been awarded a $394,300 ... ensure water quality and flow in the new ... Andrew Kruzic, UT Arlington associate professor of civil ... to add monochloramine to the water in an ... pump stations and pipelines. Adding monochloramine is widely ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... 10% of breast and ovarian cancers are familial in ... attributable to inherited mutations from the parents in genes ... mutations, PARP inhibitors, which are currently in clinical trials, ... option for personalised cancer treatment, an alternative to standard ... of these patients generate resistance to the drug and, ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |